B.01_Combined_Synopsis_and_Solicitation_W81K00-19-T-M022_Attachment_1_Required_Immunochemistry_Stains_Matrix.xlsx
XLSX spreadsheet 20 KB Posted
- Attached to
- Immunochemistry Stains
- Solicitation number
- W81K00-19-T-M022
- Issued by
-
Department of the Army Medical Command
About this file
Attachment 1 - Required Stains
View the file
Other files
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
FY19 - Base Period
| Immunochemistry Stains FY19 | |||||||
| 1 Sep to 30 to Sep 2019 | |||||||
| CPT | Description | Estimated Quantity | Unit Price per Result | Extended Price | |||
| 81210 | MOLECULAR BRAF, GENE ANALYSIS | 2 | $ - 0 | 20 | 12 | 1.67 | |
| 81235 | MOLEC EGFR GENE ANALYSIS, COMMON VARIANTS | 2 | $ - 0 | 20 | 1.67 | ||
| 81275 | KRAS GENE ANALYSIS | 1 | $ - 0 | 15 | 1.25 | ||
| 81276 | KRAS EXON 3 VARIANTS | 1 | $ - 0 | 15 | 1.25 | ||
| 81301 | MICROSATELLITE INSTABILITY ANALYSIS | 2 | $ - 0 | 20 | 1.67 | ||
| 81305 | MYD88 GENE ANALYSIS | 1 | $ - 0 | 5 | 0.42 | ||
| 81311 | NRAS EXON 2, 3 VARIANTS | 1 | $ - 0 | 5 | 0.42 | ||
| 81403 | JAK2; LEVEL 4 DNA SEQUENCE ANALYSIS | 1 | $ - 0 | 5 | 0.42 | ||
| 81404 | PIK3CA | 1 | $ - 0 | 5 | 0.42 | ||
| 88237 | TISS CULT FOR NEOPLST DISORDERS, BN MRW, BLD CELL | 1 | $ - 0 | 10 | 0.83 | ||
| 88239 | TISSUE CULTURE FOR CHROMOSOME-SOLID TUMOR | 1 | $ - 0 | 10 | 0.83 | ||
| 88261 | CHRM ANALYSIS,CT 5 CELL, 1 KAROTYPE WITH BANDING | 1 | $ - 0 | 10 | 0.83 | ||
| 88262 | CHROMOSOME ANALYSIS, 15-20 CELLS | 1 | $ - 0 | 10 | 0.83 | ||
| 88263 | CHROMOSOME ANALYSIS, COUNT 45 CELLS FOR MOSAICISM | 1 | $ - 0 | 5 | 0.42 | ||
| 88264 | CHROMOSOME ANALYSIS, 20-25 CELLS | 1 | $ - 0 | 10 | 0.83 | ||
| 88267 | CHRM ANALYSIS,AMNIO FLD OR CHORIONIC VILLUS CNT 15 CL | 1 | $ - 0 | 10 | 0.83 | ||
| 88271 | MOLECULAR CYTOGENETICS PROBE | 2 | $ - 0 | 20 | 1.67 | ||
| 88280 | CHRM ANALYSIS; ADDITIONAL KAROTYPES, EACH STUDY | 2 | $ - 0 | 20 | 1.67 | ||
| 88291 | INTERPRETATION AND REPORT | 17 | $ - 0 | 200 | 16.67 | ||
| 88305 | GROSS & MICRO, LEVEL 4 | 1 | $ - 0 | 15 | 1.25 | ||
| 88313 | SPECIAL STAIN, ROUTINE | 4 | $ - 0 | 45 | 3.75 | ||
| 88321 | PATHOLOGY SLIDE CONSULT | 3 | $ - 0 | 30 | 2.50 | ||
| 88323 | PATHOLOGY CONSULTATION WITH PROCESSING | 4 | $ - 0 | 45 | 3.75 | ||
| 88341 | IMMUNOHISTOCHEMISTRY,EACH ADDITIONAL ANTIBODY | 23 | $ - 0 | 275 | 22.92 | ||
| 88341TC | TECH ‐ IMMUNOHISTOCHEMISTRY,EACH ADDTL ANITBODY | 1 | $ - 0 | 1 | 0.08 | ||
| 88342 | IMMUNOHISTOCHEMISTRY, 1ST ANTIBODY | 8 | $ - 0 | 100 | 8.33 | ||
| 88342TC | TECH ‐ IMMUNOHISTOCHEMISTRY, 1ST ANTIBODY | 1 | $ - 0 | 1 | 0.08 | ||
| 88346 | IMMUNOFLUORESCENT STUDY, EA SPECIMEN 1ST ANTIBODY | 1 | $ - 0 | 15 | 1.25 | ||
| 88348 | ELECTRON MICROSCOPY STUDY | 1 | $ - 0 | 15 | 1.25 | ||
| 88350 | IMMUNOFLUORESCENT STUDY, EA ADDITIONAL ANTIBODY | 11 | $ - 0 | 135 | 11.25 | ||
| 88360 | QUANT IMMUNOHISTOCHEMISTRY, EACH ANTIBODY | 13 | $ - 0 | 150 | 12.50 | ||
| 88364 | TISSUE IN SITU HYBRIDIZATION, EA ADDTL PROBE | 1 | $ - 0 | 1 | 0.08 | ||
| 88365 | TISSUE IN SITU HYBRIDIZATION, 1ST PROBE | 1 | $ - 0 | 1 | 0.08 | ||
| 88377 | MORPHOMETRIC ANALYSIS, IN SITU, MANL,EA MULTIPLEX | 1 | $ - 0 | 1 | 0.08 | ||
| 88381 | MICRODISSECTION | 10 | $ - 0 | 120 | 10.00 | ||
| FY19 Base Period Total | $ - 0 |
FY20 - Option 1
| Immunochemistry Stains FY20 | |||
| 1 Oct 2019 to 30 Sep 2020 | |||
| CPT | Description | Estimated Quantity | |
| Unit Price per Result | Extended Price | ||
| 81210 | MOLECULAR BRAF, GENE ANALYSIS | 20 | $ - 0 |
| 81235 | MOLEC EGFR GENE ANALYSIS, COMMON VARIANTS | 20 | $ - 0 |
| 81275 | KRAS GENE ANALYSIS | 15 | $ - 0 |
| 81276 | KRAS EXON 3 VARIANTS | 15 | $ - 0 |
| 81301 | MICROSATELLITE INSTABILITY ANALYSIS | 20 | $ - 0 |
| 81305 | MYD88 GENE ANALYSIS | 5 | $ - 0 |
| 81311 | NRAS EXON 2, 3 VARIANTS | 5 | $ - 0 |
| 81403 | JAK2; LEVEL 4 DNA SEQUENCE ANALYSIS | 5 | $ - 0 |
| 81404 | PIK3CA | 5 | $ - 0 |
| 88237 | TISS CULT FOR NEOPLST DISORDERS, BN MRW, BLD CELL | 10 | $ - 0 |
| 88239 | TISSUE CULTURE FOR CHROMOSOME-SOLID TUMOR | 10 | $ - 0 |
| 88261 | CHRM ANALYSIS,CT 5 CELL, 1 KAROTYPE WITH BANDING | 10 | $ - 0 |
| 88262 | CHROMOSOME ANALYSIS, 15-20 CELLS | 10 | $ - 0 |
| 88263 | CHROMOSOME ANALYSIS, COUNT 45 CELLS FOR MOSAICISM | 5 | $ - 0 |
| 88264 | CHROMOSOME ANALYSIS, 20-25 CELLS | 10 | $ - 0 |
| 88267 | CHRM ANALYSIS,AMNIO FLD OR CHORIONIC VILLUS CNT 15 CL | 10 | $ - 0 |
| 88271 | MOLECULAR CYTOGENETICS PROBE | 20 | $ - 0 |
| 88280 | CHRM ANALYSIS; ADDITIONAL KAROTYPES, EACH STUDY | 20 | $ - 0 |
| 88291 | INTERPRETATION AND REPORT | 200 | $ - 0 |
| 88305 | GROSS & MICRO, LEVEL 4 | 15 | $ - 0 |
| 88313 | SPECIAL STAIN, ROUTINE | 45 | $ - 0 |
| 88321 | PATHOLOGY SLIDE CONSULT | 30 | $ - 0 |
| 88323 | PATHOLOGY CONSULTATION WITH PROCESSING | 45 | $ - 0 |
| 88341 | IMMUNOHISTOCHEMISTRY,EACH ADDITIONAL ANTIBODY | 275 | $ - 0 |
| 88341TC | TECH ‐ IMMUNOHISTOCHEMISTRY,EACH ADDTL ANITBODY | 1 | $ - 0 |
| 88342 | IMMUNOHISTOCHEMISTRY, 1ST ANTIBODY | 100 | $ - 0 |
| 88342TC | TECH ‐ IMMUNOHISTOCHEMISTRY, 1ST ANTIBODY | 1 | $ - 0 |
| 88346 | IMMUNOFLUORESCENT STUDY, EA SPECIMEN 1ST ANTIBODY | 15 | $ - 0 |
| 88348 | ELECTRON MICROSCOPY STUDY | 15 | $ - 0 |
| 88350 | IMMUNOFLUORESCENT STUDY, EA ADDITIONAL ANTIBODY | 135 | $ - 0 |
| 88360 | QUANT IMMUNOHISTOCHEMISTRY, EACH ANTIBODY | 150 | $ - 0 |
| 88364 | TISSUE IN SITU HYBRIDIZATION, EA ADDTL PROBE | 1 | $ - 0 |
| 88365 | TISSUE IN SITU HYBRIDIZATION, 1ST PROBE | 1 | $ - 0 |
| 88377 | MORPHOMETRIC ANALYSIS, IN SITU, MANL,EA MULTIPLEX | 1 | $ - 0 |
| 88381 | MICRODISSECTION | 120 | $ - 0 |
| FY20 OY1 Period Total | $ - 0 |
FY21 - Option 2
| Immunochemistry Stains FY21 | |||
| 1 Oct 2020 to 30 Sep 2021 | |||
| CPT | Description | Estimated Quantity | |
| Unit Price per Result | Extended Price | ||
| 81210 | MOLECULAR BRAF, GENE ANALYSIS | 20 | $ - 0 |
| 81235 | MOLEC EGFR GENE ANALYSIS, COMMON VARIANTS | 20 | $ - 0 |
| 81275 | KRAS GENE ANALYSIS | 15 | $ - 0 |
| 81276 | KRAS EXON 3 VARIANTS | 15 | $ - 0 |
| 81301 | MICROSATELLITE INSTABILITY ANALYSIS | 20 | $ - 0 |
| 81305 | MYD88 GENE ANALYSIS | 5 | $ - 0 |
| 81311 | NRAS EXON 2, 3 VARIANTS | 5 | $ - 0 |
| 81403 | JAK2; LEVEL 4 DNA SEQUENCE ANALYSIS | 5 | $ - 0 |
| 81404 | PIK3CA | 5 | $ - 0 |
| 88237 | TISS CULT FOR NEOPLST DISORDERS, BN MRW, BLD CELL | 10 | $ - 0 |
| 88239 | TISSUE CULTURE FOR CHROMOSOME-SOLID TUMOR | 10 | $ - 0 |
| 88261 | CHRM ANALYSIS,CT 5 CELL, 1 KAROTYPE WITH BANDING | 10 | $ - 0 |
| 88262 | CHROMOSOME ANALYSIS, 15-20 CELLS | 10 | $ - 0 |
| 88263 | CHROMOSOME ANALYSIS, COUNT 45 CELLS FOR MOSAICISM | 5 | $ - 0 |
| 88264 | CHROMOSOME ANALYSIS, 20-25 CELLS | 10 | $ - 0 |
| 88267 | CHRM ANALYSIS,AMNIO FLD OR CHORIONIC VILLUS CNT 15 CL | 10 | $ - 0 |
| 88271 | MOLECULAR CYTOGENETICS PROBE | 20 | $ - 0 |
| 88280 | CHRM ANALYSIS; ADDITIONAL KAROTYPES, EACH STUDY | 20 | $ - 0 |
| 88291 | INTERPRETATION AND REPORT | 200 | $ - 0 |
| 88305 | GROSS & MICRO, LEVEL 4 | 15 | $ - 0 |
| 88313 | SPECIAL STAIN, ROUTINE | 45 | $ - 0 |
| 88321 | PATHOLOGY SLIDE CONSULT | 30 | $ - 0 |
| 88323 | PATHOLOGY CONSULTATION WITH PROCESSING | 45 | $ - 0 |
| 88341 | IMMUNOHISTOCHEMISTRY,EACH ADDITIONAL ANTIBODY | 275 | $ - 0 |
| 88341TC | TECH ‐ IMMUNOHISTOCHEMISTRY,EACH ADDTL ANITBODY | 1 | $ - 0 |
| 88342 | IMMUNOHISTOCHEMISTRY, 1ST ANTIBODY | 100 | $ - 0 |
| 88342TC | TECH ‐ IMMUNOHISTOCHEMISTRY, 1ST ANTIBODY | 1 | $ - 0 |
| 88346 | IMMUNOFLUORESCENT STUDY, EA SPECIMEN 1ST ANTIBODY | 15 | $ - 0 |
| 88348 | ELECTRON MICROSCOPY STUDY | 15 | $ - 0 |
| 88350 | IMMUNOFLUORESCENT STUDY, EA ADDITIONAL ANTIBODY | 135 | $ - 0 |
| 88360 | QUANT IMMUNOHISTOCHEMISTRY, EACH ANTIBODY | 150 | $ - 0 |
| 88364 | TISSUE IN SITU HYBRIDIZATION, EA ADDTL PROBE | 1 | $ - 0 |
| 88365 | TISSUE IN SITU HYBRIDIZATION, 1ST PROBE | 1 | $ - 0 |
| 88377 | MORPHOMETRIC ANALYSIS, IN SITU, MANL,EA MULTIPLEX | 1 | $ - 0 |
| 88381 | MICRODISSECTION | 120 | $ - 0 |
| FY21 OY1 Period Total | $ - 0 |
File details come from the government source that posted it.